JNJ-90301900 (NBTXR3)

Phase 3

47%

Phase 3

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts

Jun 30

JNJ⭐Phase 3Phase 3

JNJ-90301900 (NBTXR3) Phase 3 Results Expected

JNJ-90301900 (NBTXR3) • Locally Advanced Head and Neck Squamous Cell Carcinoma

Drug Information

Target Indication

Locally Advanced Head and Neck Squamous Cell Carcinoma

Clinical Trial

Last updated: 12/5/2025

Developer

JNJ

Johnson & Johnson